Vetter Brand Guidelines: A Ravensburg Pharmacy That Turned to Prefilled Syringes

A pharmacist, a stomach remedy and a turn to syringes.

Vetter began in Ravensburg, in Upper Swabia, with a pharmacist. The company’s own history says Helmut Vetter founded a chemical and pharmaceutical laboratory in Ravensburg in 1945, with a drug production unit and a school for laboratory technicians, and in 1950 leased the town’s Marien-Apotheke and founded the Vetter Pharma family business. English Wikipedia gives the name of the 1950 company as “Apotheker Vetter & Co. Arzneimittel GmbH Ravensburg.”

Its first product was a stomach remedy. The company says that in 1954 Helmut Vetter developed Ullus, a medicine in wafer capsules, a tasteless way of taking a stomach preparation, which was exported as far as the United States; English Wikipedia also names the Ullus capsules as the early mainstay. In 1958, the company says, it moved to larger premises and took over the pharmacy on Marienplatz, adding special teas and a teething gel to its range.

The turn toward contract work came in 1965, when, according to both the company and English Wikipedia, Vetter began manufacturing medicines for other firms, including liquids such as contact lens solutions. The company dates Helmut Vetter’s idea for a ready-to-use prefilled syringe to 1979 and says that in 1981 it stopped making tablets, capsules, powders and contact lens fluids to concentrate on syringes. English Wikipedia describes a gradual shift: aseptically prefilled syringes from 1975, and aseptic filling as the main business by the end of the 1980s.

In 1984 the company took the name Vetter Pharma-Fertigung GmbH & Co. KG, English Wikipedia says, a year after setting up its first foreign subsidiary, a sales company in Yardley, Pennsylvania, to serve the United States and Canada. Udo J. Vetter took on management roles in 1987. The company says that in 2008 the business passed to the second generation, with all the Vetter family branches represented and Udo J. Vetter as chairman of the owner families.

Filling other companies’ injectable drugs.

Vetter is a contract development and manufacturing organisation, or CDMO, for injectable drugs. English Wikipedia describes its work as aseptic fill-and-finish for vials, syringes and cartridges, together with clinical and commercial manufacturing, device assembly, packaging and lifecycle management; the active ingredients it fills belong to its pharmaceutical customers.

The step that opened the American market came in 1988, when, English Wikipedia says, the US Food and Drug Administration approved the Ravensburg plant; the company then employed around 350 people. In 1990 Vetter launched a dual-chamber syringe, which holds a freeze-dried drug in one chamber and its solvent in the other, to be mixed at the moment of use. The company calls it the Lyo-Ject, and says it first used robots in its aseptic production two years later.

Its commercial plants are in Germany. A second production site opened at Langenargen on Lake Constance in 1996 and received FDA approval in 1998; a plant at Ravensburg South, in the Mariatal industrial estate, was built from 2004, approved by the Tübingen regional council in 2007 and by the FDA a year later, and a final-packaging plant followed in 2009, English Wikipedia says. The company adds a centre for visual inspection and logistics at Ravensburg West, opened in 2013, which it says won the ISPE Facility of the Year Award in the “Facility of the Future” category in 2019.

Clinical work runs at smaller sites. The company says its first US production site opened in Skokie, outside Chicago, in 2012, while English Wikipedia gives 2011. A clinical site at Rankweil, in Austria’s Vorarlberg, received its operating approval at the end of 2021 after an inspection by the Austrian agency AGES, English Wikipedia says. The same source says the US development site is moving from Skokie to nearby Des Plaines, where construction began in June 2025. Sales offices followed in Asia from the mid-2010s, in Singapore, Japan and South Korea, and in Shanghai in 2021.

Contract manufacturing for medicines.

Contract development and manufacturing organisations, or CDMOs, make medicines for other companies. A drug developer may hand them a cell line, a molecule or a finished formula, and the partner develops the process, makes the drug substance, fills it into vials, syringes or capsules and packs it for trials or for sale. Most of that work happens out of public view, under the customer’s name rather than the maker’s, so the manufacturer’s own brand speaks mainly to other businesses.

The imagery of the trade is fairly consistent. Websites and brochures tend to show tall stainless-steel bioreactors and rows of single-use bags in bright, white production suites; operators in full gowns, hoods and gloves working in cleanrooms; and filling lines carrying glass vials. Aerial photographs of large new plants, often shown under construction or on opening day, stand in for scale, and site maps of a global network do the same job for reach.

Much of the brand work happens at trade events. CPHI, the pharmaceutical trade fair, and the BIO International Convention in the United States are where these companies take stands, announce deals and, at times, unveil new identities: Pharma Manufacturing reported that Catalent introduced its new corporate brand at CPHI Frankfurt in 2025.

This guide sets out what can be checked about each company — where it began, who owns it now, which sites and services it describes, and what has been reported about it — and separates documented facts from what the companies say about themselves. The colours and typefaces used here are our own interpretation, not official brand assets.

A family company building in Saarlouis.

Vetter is still owned by the founding family. The company calls itself a family business; Udo J. Vetter chairs its independent advisory board, and its managing directors are Henryk Badack, Titus Ottinger and Carsten Press, according to English Wikipedia. The company marked 75 years in 2025, counting from 1950.

Its largest new project is in the Saarland. In May 2026 Vetter began building a plant on the former Ford site at Saarlouis, where, ZDF heute reported on 16 May 2026, the last Ford had left the line in November 2025. CHEManager reported on 18 May 2026 that the site of roughly 40 hectares will be used for the commercial manufacture of injectable drugs, with a production building of 50,000 square metres and, at first, three cleanrooms: two for filling pre-sterilised syringes and one for vials. Operations are planned to start in 2031. The company expects 400 to 500 jobs at first and up to 1,500 by the end of the first phase, with up to 2,000 possible in the longer term, the magazine reported. In June 2024 the company had also announced capacity expansions at Ravensburg and Langenargen, English Wikipedia says.

The company’s recognitions are listed by English Wikipedia: the Sustainable Impact Award from WirtschaftsWoche and its partners in 2022 and 2023, the German environment ministry’s Environmental Management Award in 2023, and the Best Managed Companies award from Deloitte, the Frankfurter Allgemeine Zeitung, the BDI and UBS for a fifth consecutive time in 2024. In 2024 Vetter opened a training centre in Ravensburg for pharmaceutical and chemical laboratory technicians, which the company says covers more than 5,000 square metres.

For a design guide, Vetter shows how a family name can carry a business from a town pharmacy to a supplier that fills other companies’ medicines at sites in Europe and the United States. Compare Recipharm, which also fills sterile drugs, and Catalent, another contract manufacturer. For this guide we use a deep teal, a warm grey and a soft white with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Vetter’s identity on hand — save it to a board in the Made Good inspiration library.